between effective radiation dose and outcome of radioiodine therapy for thyroid cancer . N Engl J Med 1983 ; 309 : 937 – 941 . 16. Maxon HR III Englaro EE Thomas SR . Radioiodine-131 therapy for well-differentiated thyroid cancer
Search Results
Ashley E. Rosko, Sarah Wall, Robert Baiocchi, Don M. Benson, Jonathan E. Brammer, John C. Byrd, Yvonne A. Efebera, Kami Maddocks, Kerry A. Rogers, Desiree Jones, Lara Sucheston-Campbell, Hancong Tang, Hatice Gulcin Ozer, Ying Huang, Christin E. Burd, and Michelle J. Naughton
(mPhenoAge), has recently been reported, which is able to capture risk of adverse clinical outcomes across diverse tissue types 19 ; mPhenoAge has not yet been evaluated in a population with blood cancer. In this study, we explored mPhenoAge, markers of
Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming
treatment with a non–EGFR-targeting regimen. We analyzed disease bulk as an independent predictor of clinical outcomes associated with anti-EGFR therapies to build on the impact of sidedness in the treatment-refractory setting. Using a single
Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
and the ICI therapy course and lead to morbidity and mortality. Given the limited data on IMM, we evaluated the clinical characteristics, disease course, treatment, and outcome of IMM in patients at a tertiary cancer center. Methods Study
Arjun Gupta, Avash Das, Raseen Tariq, Nizar Bhulani, Naveen Premnath, Dipesh Solanky, Ryan D. Frank, David Johnson, Sahil Khanna, and Muhammad S. Beg
questionable. Within the past few decades, ICU outcomes have improved drastically, owing to better management techniques, early identification of sicker patients, and more lenient admission criteria for ICUs. One recent study reported a 35% relative decrease
Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh, Huiwen Xu, Amita Patil, Nikesha Gilmore, Spencer Obrecht, Megan Wells, Ginah Nightingale, Katherine M. Juba, Bryan Faller, Adedayo Onitilo, Thomas Bradley, Eva Culakova, Holly Holmes, and Supriya G. Mohile
supportive care medications can increase the potential for clinically significant drug–drug interactions and adverse outcomes. 8 Polypharmacy is also associated with an increased risk of taking potentially inappropriate medications (PIMs; medications with a
Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna
Thus, elucidating the epidemiology of CDI and its impact on outcomes in patients with cancer is imperative. We used the National Hospital Discharge Survey (NHDS) database to evaluate the incidence of CDI in patients with both solid organ and
Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson
,739 postmenopausal women with prior hysterectomy 12 ( Figure 1 ). The primary outcome monitored for benefit was coronary heart disease and the primary outcome monitored for harm was invasive breast cancer. A global index of time to first Figure 1 Women
Nora Janjan
Patient outcomes have become an integral end point as the nation’s medical training, research, and delivery system transforms into a patient-centered, value-based accreditation and reimbursement system. The components of patient-centered outcomes
Paul A. Glare
palliative care-type treatment, given that this term is perceived to cause less distress to patients, their caregivers, and clinicians. 7 , 21 Symptom control and, therefore, quality of life are the end points of supportive care, while the main outcome is
